

Akihiko Sato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/777695/publications.pdf>

Version: 2024-02-01

35
papers

1,816
citations

430874

18
h-index

361022

35
g-index

37
all docs

37
docs citations

37
times ranked

2187
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection. <i>Viruses</i> , 2022, 14, 111.	3.3	6
2	Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 189-198.	3.0	10
3	MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2. <i>Scientific Reports</i> , 2021, 11, 5376.	3.3	18
4	A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site. <i>Immunity</i> , 2021, 54, 2385-2398.e10.	14.3	46
5	Attenuated infection by a Pteropine orthoreovirus isolated from an Egyptian fruit bat in Zambia. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009768.	3.0	7
6	5-Hydroxymethyltubercidin exhibits potent antiviral activity against flaviviruses and coronaviruses, including SARS-CoV-2. <i>IScience</i> , 2021, 24, 103120.	4.1	6
7	Air-liquid interphase culture confers SARS-CoV-2 susceptibility to A549 alveolar epithelial cells. <i>Biochemical and Biophysical Research Communications</i> , 2021, 577, 146-151.	2.1	14
8	SARS-CoV-2 variants with mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells. <i>PLoS Pathogens</i> , 2021, 17, e1009233.	4.7	162
9	Identification of quinolone derivatives as effective anti-Dengue virus agents. <i>Antiviral Research</i> , 2020, 184, 104969.	4.1	5
10	The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets. <i>Influenza and Other Respiratory Viruses</i> , 2020, 14, 710-719.	3.4	6
11	Inhibition of dengue virus infection by 1- <i>sn</i> -sn-3'-phosphatidylinositol <i>in vitro</i> . <i>FASEB Journal</i> , 2019, 33, 13866-13881.	0.5	10
12	Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models. <i>PLoS ONE</i> , 2019, 14, e0217307.	2.5	33
13	Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil. <i>Scientific Reports</i> , 2019, 9, 3466.	3.3	25
14	Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors. <i>Antiviral Research</i> , 2018, 152, 1-9.	4.1	19
15	In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. <i>Antiviral Research</i> , 2018, 160, 109-117.	4.1	246
16	Identification of Compound-B, a novel anti-dengue virus agent targeting the non-structural protein 4A. <i>Antiviral Research</i> , 2018, 155, 60-66.	4.1	19
17	Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation. <i>Antiviral Research</i> , 2017, 139, 41-48.	4.1	6
18	Discovery of novel 5-hydroxy-4-pyridone-3-carboxy acids as potent inhibitors of influenza Cap-dependent endonuclease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4739-4742.	2.2	11

#	ARTICLE	IF	CITATIONS
19	Effects of Raltegravir or Elvitegravir Resistance Signature Mutations on the Barrier to Dolutegravir Resistance <i><i>In Vitro</i></i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2596-2606.	3.2	33
20	Antiviral Characteristics of GSK1265744, an HIV Integrase Inhibitor Dosed Orally or by Long-Acting Injection. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 397-406.	3.2	84
21	Efficacy of Repeated Intravenous Administration of Peramivir against Highly Pathogenic Avian Influenza A (H5N1) Virus in Cynomolgus Macaques. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4795-4803.	3.2	19
22	The relationship between <i>in vivo</i> antiviral activity and pharmacokinetic parameters of peramivir in influenza virus infection model in mice. <i>Antiviral Research</i> , 2014, 109, 110-115.	4.1	6
23	Hemozoin is a potent adjuvant for hemagglutinin split vaccine without pyrogenicity in ferrets. <i>Vaccine</i> , 2014, 32, 3004-3009.	3.8	10
24	Carbamoyl Pyridone HIV-1 Integrase Inhibitors 3. A Diastereomeric Approach to Chiral Nonracemic Tricyclic Ring Systems and the Discovery of Dolutegravir (S/GSK1349572) and (S/GSK1265744). <i>Journal of Medicinal Chemistry</i> , 2013, 56, 5901-5916.	6.4	161
25	Prevalent Polymorphisms in Wild-Type HIV-1 Integrase Are Unlikely To Engender Drug Resistance to Dolutegravir (S/GSK1349572). <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1379-1384.	3.2	18
26	Efficacy of Repeated Intravenous Injection of Peramivir against Influenza A (H1N1) 2009 Virus Infection in Immunosuppressed Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2286-2294.	3.2	14
27	<i><i>In Vitro</i></i> Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 813-821.	3.2	346
28	Efficacy of Single Intravenous Injection of Peramivir against Influenza B Virus Infection in Ferrets and Cynomolgus Macaques. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4961-4970.	3.2	31
29	Establishment of a cynomolgus macaque model of influenza B virus infection. <i>Virology</i> , 2010, 407, 178-184.	2.4	19
30	Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics. <i>Antiviral Research</i> , 2009, 81, 141-146.	4.1	50
31	Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. <i>Antiviral Research</i> , 2008, 80, 213-222.	4.1	100
32	The Naphthyridinone GSK364735 Is a Novel, Potent Human Immunodeficiency Virus Type 1 Integrase Inhibitor and Antiretroviral. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 901-908.	3.2	71
33	<i>In vitro</i> selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor. <i>Antiviral Research</i> , 2006, 70, 66-74.	4.1	21
34	Small Amino Acid Changes in the V3 Loop of Human Immunodeficiency Virus Type 2 Determines the Coreceptor Usage for CXCR4 and CCR5. <i>Virology</i> , 1999, 264, 237-243.	2.4	47
35	S-1153 Inhibits Replication of Known Drug-Resistant Strains of Human Immunodeficiency Virus Type 1. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 1340-1345.	3.2	129